Zenodo (CERN)
open access
CC BY-NC 4.0
IN SILICO DESIGN AND EVALUATION OF NOVEL BENZOXAZINE DERIVATIVES AS POTENTIAL CDK9 INHIBITORS FOR ANTICANCER THERAPY
Cyclin-Dependent Kinase 9 (CDK9) is a crucial regulator of tumour cell proliferation, survival, and oncogenic gene expression. Transcriptional dysregulation is a known hallmark of cancer. In this work, a novel series of compounds containing benzoxazine was designed and eva
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- A patent perspective of RSK inhibitors to treat cancer (2020-present).#631504
- Identification of benzoxazine scaffold derivatives as novel CDK4 inhibitors for the treatment of cancer.#1167202
- Pharmacogenomic and Circulating Biomarkers for CDK4/6 Inhibitors#979516
- Phase II, Single-arm Study of AZD1775 Monotherapy in Relapsed Small Cell Lung Cancer Patients With MYC Family Amplification or CDKN2A Mutation Combined With TP53 Mutation#894128
- DSP-0390 in Combination With Atezolizumab for Small Cell Lung Cancer#125821
Record · ID 990680
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive